- Saya Biologics has entered a strategic partnership with Enzene Biosciences to develop and manufacture two biosimilar therapies targeting osteoporosis for the Mexican market.
- Saya Bio will manage regulatory approval, commercialisation and distribution, while Enzene will provide CDMO development and manufacturing services.
Saya Biologics has announced a strategic partnership with Enzene Biosciences to support the development and manufacture of two biologic therapies for osteoporosis in Mexico. The agreement combines Enzene’s CDMO capabilities with Saya Bio’s role in registration, commercialisation and distribution of biosimilars for the Mexican healthcare system.
The collaboration addresses a significant public health need. According to the National Institute of Rehabilitation “Luis Guillermo Ibarra Ibarra,” osteoporosis affects 10 million people in Mexico. The companies stated that their partnership aims to increase access to safe, effective and affordable treatments for patients living with chronic bone and joint conditions.
Enzene will oversee development and manufacturing activities for both products, applying its continuous manufacturing technologies and biologics expertise. Saya Bio will lead market entry planning, regulatory submissions and commercial rollout across Mexico.
“We are excited to partner with Enzene to improve access to bone health therapies in Mexico,” said Adrián García, CEO of Saya Bio. He noted the potential of these treatments to improve the quality of life for millions of patients who face financial and access barriers.
“The partnership reflects the company’s commitment to supporting affordable and accessible biologic medicines through its development and manufacturing capabilities.”
Himanshu Gadgil, CEO of Enzene Biosciences
